Korro Bio’s Promising KRRO-110 Developments and Strong Financial Position Justify Buy Rating
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Korro Bio (KRRO – Research Report). The associated price ...
Business Insider1d
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
Nov. 12, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and ...
manilatimes1d
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Research and development expenses increased to $17.0 million for the three months ended September 30, 2024 from $15.4 million for the three months ended September 30, 2023 primarily due to ...
Investing6d
4 Biotech Stocks With AI, Machine Learning Prowess
Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...